Treatment options for advanced lung cancer with specific genetic mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates various treatment strategies and their impact on survival outcomes for patients with non-small cell lung cancer (NSCLC) that have specific oncogenic mutations such as EGFR, ALK, ROS1, and MET. Participants will receive targeted therapies including Osimertinib, Alectinib, and Crizotinib, among others, based on their genetic profile. The study aims to determine the effectiveness of these treatments in improving patient survival and quality of life. It involves a comprehensive assessment of treatment responses and side effects in a controlled environment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
2. Age ≥ 18 years.
3. Histologically or cytologically confirmed, Stage IV NSCLC.
4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
5. ECOG 0-1.
6. Predicted survival ≥ 12 weeks.
7. Adequate bone marrow hematopoiesis and organ function
8. Presence of measurable lesions according to RECIST 1.1.

Exclusion Criteria:

The patient did not match from the Inclusion Criteria.

Where it's running

• Yongchang Zhang
  Changsha, Hunan, China Recruiting

Study contacts

• Principal investigator: Yongchang Zhang, MD — Hunan Cancer Hospital
• Study coordinator: Yongchang Zhang, MD
• Email: zhangyongchang@csu.edu.cn
• Phone: +8613873123436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying tumor survival mechanisms in lung cancer after targeted therapy

  This study is trying to see how lung cancer tumors change before and after treatment with a specific drug to find ways to make the treatment work better.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT03042221

• Combining nitroglycerin with radiation therapy for lung cancer patients with brain metastases

  This study is testing if adding nitroglycerin to radiation therapy can help lung cancer patients with brain metastases live longer and feel better.

  Recruiting Instituto Nacional de Cancerologia de Mexico · Mexico City, Mexico City · NCT06238882

• Combining Nintedanib with EGFR inhibitors for advanced lung cancer

  This study is testing if combining a medication called Nintedanib with EGFR inhibitors can help people with advanced lung cancer who haven't responded to previous treatments.

  Recruiting Phase 1/2 China Medical University Hospital · Taichung · NCT06071013

• Combining Alectinib with Radiation Therapy for Advanced Lung Cancer with ALK Mutation

  This study is testing if combining alectinib with targeted radiation therapy can help people with advanced lung cancer that has an ALK mutation feel better and live longer.

  Recruiting Karolinska University Hospital · Stockholm · NCT05724004

• Evaluating Osimertinib with Early Stereotactic Radiosurgery for EGFR Mutated NSCLC with Brain Metastases

  This study is testing if combining a lung cancer drug called Osimertinib with early targeted radiation therapy can help people with EGFR-mutated non-small cell lung cancer and brain metastases live longer and maintain better brain function.

  Recruiting Hadassah Medical Organization · Jerusalem · NCT05033691

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.